［1］ Xie J F, Wu W J, Li S S, et al. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study［J］. Intensive Care Med, 2020, 46(10): 1863-1872.
［2］ Tang X, Du R H, Wang R, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1［J］. Chest, 2020, 158(1): 195-205.
［3］ Qiu H B, Tong Z H, Ma P L, et al. Intensive care during the coronavirus epidemic［J］. Intensive Care Med, 2020, 46(4):576-578.
［4］ Xu J Y, Xie J F, Du B, et al. Clinical characteristics and outcomes of patients with severe COVID-19 induced acute kidney injury［J］. J Intensive Care Med, 2021,36(3):319-326.
［5］ Kang H, Gu X, Tong Z. Effect of awake prone positioning in non-intubated COVID-19 patients with acute hypoxemic respiratory failure: a systematic review and Meta-analysis［J］. J Intensive Care Med, 2022 ,37(11):1493-1503.
［6］ Yang H, Wang Z J, Zhang Y, et al. Clinical characteristics and factors for serious outcomes among outpatients infected with the Omicron subvariant BF.7［J］. J Med Virol, 2023, 95(8): e28977.
［7］ Wang F, Wang Z, Tong Z, et al. A pilot study of autofluorescence in the diagnosis of pleural disease［J］. Chest, 2015, 147(5): 1395-1400.
［8］ Hu Y, Wang D, Zhai K, et al. Transcriptomic analysis reveals significant B lymphocyte suppression in corticosteroid-treated hosts with pneumocystis pneumonia［J］. Am J Respir Cell Mol Biol, 2017, 56(3): 322-331.
［9］ Zhang C, Rong H M, Li T, et al. PD-1 deficiency promotes macrophage activation and T-helper cell type 1/T-helper cell type 17 response in pneumocystis pneumonia［J］. Am J Respir Cell Mol Biol, 2020, 62(6): 767-782.
［10］ Liang L R, Cai Y T, Barratt B, et al. Associations between daily air quality and hospitalisations for acute exacerbation of chronic obstructive pulmonary disease in Beijing, 2013-17: an ecological analysis［J］. Lancet Planet Health, 2019, 3(6): e270-e279.
|
